Detectability of EOB-MRI for pancreatic liver metastases after neoadjuvant chemotherapy

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-jRCT1060220019

Enrollment

211

Registered

2022-05-25

Start date

2022-05-25

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pancreatic cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Pancreatic cancer undergoing Neoadjuvant chemotherapy Resectable and Borderline resectable pancreatic cancer

Exclusion criteria

Exclusion criteria: Contraindications for contrast enhanced CT or EOB-MRI Performance status 2,3,4 younger than 20 years old patients

Design outcomes

Primary

Measure	Time frame
sensitivity of EOB-MRI for liver metastasis after Neoadjuvant chemotherapy	—

Secondary

Measure	Time frame
specificity, accuracy, positive predictive value,negative predictive value of EOB-MRI for liver metastasis after Neoadjuvant chemotherapy risk factor for liver metastasis after Neoadjuvant chemotherapy	—

Contacts

Public ContactYuki Fujii

Department of Gastroenterology and Hepatology

y_f1105@yahoo.co.jp+81-86-235-7219

Outcome results